Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synbiotic 2000
- Development stage
- Phase 4
- Lead developer
- Synbiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Synbiotic 2000 is a multi-strain synbiotic preparation consisting of four probiotic bacteria (*Pediococcus pentosaceus* 5-33:3, *Leuconostoc mesenteroides* 77:1, *Lactobacillus paracasei* subsp. *paracasei* 19, and *Lactobacillus plantarum* 2362) and four fermentable prebiotic fibers (betaglucan, inulin, pectin, and resistant starch). Developed by Synbiotic AB, it is designed to restore gut microbiota balance and modulate the immune system to reduce systemic inflammation and the risk of infections. It has been studied in various clinical settings, including post-operative recovery (e.g., cardiac and abdominal surgery), liver transplantation, and critical illness, to prevent complications like sepsis and surgical site infections.
- Brand names
- Synbiotic 2000Synbiotic2000Synbiotic-2000
- Other names
- Synbiotic Cocktail 2000Synbiotic 2000 ForteSynbiotic2000 ForteSynbiotic-2000 Forte
Beyond the preview
Go deeper on Synbiotic 2000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synbiotic 2000.